A genomic approach to therapeutic target validation identifies a glucose-lowering
GLP1R
variant protective for coronary heart disease
Authors: Scott Robert A. , Freitag Daniel F. , Li Li , Chu Audrey Y. , Surendran Praveen , Young Robin , Grarup Niels , Stancáková Alena , Chen Yuning , Varga Tibor V. , Yaghootkar Hanieh , Luan Jian’an , Zhao Jing Hua , Willems Sara M. , Wessel Jennifer , Wang Shuai , Maruthur Nisa , Michailidou Kyriaki , Pirie Ailith , van der Lee Sven J. , Gillson Christopher , Al Olama Ali Amin , Amouyel Philippe , Arriola Larraitz , Arveiler Dominique , Aviles-Olmos Iciar , Balkau Beverley , Barricarte Aurelio , Barroso Inês , Garcia Sara Benlloch , Bis Joshua C. , Blankenberg Stefan , Boehnke Michael , Boeing Heiner , Boerwinkle Eric , Borecki Ingrid B. , Bork-Jensen Jette , Bowden Sarah , Caldas Carlos , Caslake Muriel ,   The CVD50 consortium, Cupples L. Adrienne , Cruchaga Carlos , Czajkowski Jacek , den Hoed Marcel , Dunn Janet A. , Earl Helena M. , Ehret Georg B. , Ferrannini Ele , Ferrieres Jean , Foltynie Thomas , Ford Ian , Forouhi Nita G. , Gianfagna Francesco , Gonzalez Carlos , Grioni Sara , Hiller Louise , Jansson Jan-Håkan , Jørgensen Marit E. , Jukema J. Wouter , Kaaks Rudolf , Kee Frank , Kerrison Nicola D. , Key Timothy J. , Kontto Jukka , Kote-Jarai Zsofia , Kraja Aldi T. , Kuulasmaa Kari , Kuusisto Johanna , Linneberg Allan , Liu Chunyu , Marenne Gaëlle , Mohlke Karen L. , Morris Andrew P. , Muir Kenneth , Müller-Nurasyid Martina , Munroe Patricia B. , Navarro Carmen , Nielsen Sune F. , Nilsson Peter M. , Nordestgaard Børge G. , Packard Chris J. , Palli Domenico , Panico Salvatore , Peloso Gina M. , Perola Markus , Peters Annette , Poole Christopher J. , Quirós J. Ramón , Rolandsson Olov , Sacerdote Carlotta , Salomaa Veikko , Sánchez María-José , Sattar Naveed , Sharp Stephen J. , Sims Rebecca , Slimani Nadia , Smith Jennifer A. , Thompson Deborah J. , Trompet Stella , Tumino Rosario , van der A Daphne L. , van der Schouw Yvonne T. , Virtamo Jarmo , Walker Mark , Walter Klaudia ,   GERAD_EC Consortium,   Neurology Working Group of the Cohorts for Heart,   Aging Research in Genomic Epidemiology (CHARGE),   Alzheimer’s Disease Genetics Consortium,   Pancreatic Cancer Cohort Consortium,   European Prospective Investigation into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD),   EPIC-InterAct, Abraham Jean E. , Amundadottir Laufey T. , Aponte Jennifer L. , Butterworth Adam S. , Dupuis Josée , Easton Douglas F. , Eeles Rosalind A. , Erdmann Jeanette , Franks Paul W. , Frayling Timothy M. , Hansen Torben , Howson Joanna M. M. , Jørgensen Torben , Kooner Jaspal , Laakso Markku , Langenberg Claudia , McCarthy Mark I. , Pankow James S. , Pedersen Oluf , Riboli Elio , Rotter Jerome I. , Saleheen Danish , Samani Nilesh J. , Schunkert Heribert , Vollenweider Peter , O’Rahilly Stephen ,   CHARGE consortium,   The CHD Exome+ Consortium,   CARDIOGRAM Exome Consortium, Deloukas Panos , Danesh John , Goodarzi Mark O. , Kathiresan Sekar , Meigs James B. , Ehm Margaret G. , Wareham Nicholas J. , Waterworth Dawn M. 
Published: June 2016

A missense variant in GLP1R associated with lower fasting glucose levels and protective against T2D is associated with lower risk of coronary heart disease, suggesting that GLP1R agonists are not associated with an unacceptable increase in cardiovascular risk.